NeoGenomics, Inc. (NASDAQ: NEO) announced the commercial availability of PanTracer Pro, a new addition to its PanTracer family of oncology diagnostics. The test combines broad DNA and RNA sequencing of over 500 cancer‑related genes with tumor‑specific immunohistochemistry and ancillary testing, all within a single coordinated order.
PanTracer Pro delivers results in 8–10 days, a turnaround that supports timely treatment decisions for patients with advanced‑stage solid tumors. The platform also includes an automatic reflex to NeoGenomics’ PanTracer Liquid Biopsy assay when tissue samples are insufficient, allowing clinicians to continue the diagnostic workup without restarting the process.
The launch expands NeoGenomics’ portfolio of high‑value next‑generation sequencing (NGS) products and positions the company to capture a larger share of the growing precision‑oncology market, where rapid, comprehensive profiling is increasingly demanded by community oncologists and hospitals. NeoGenomics has been actively developing and launching products within the PanTracer family, including PanTracer Tissue and PanTracer LBx, and the company emphasizes its focus on the community oncology setting.
NeoGenomics’ Q4 2025 revenue reached $190 million, an 11% year‑over‑year increase, and the company projects full‑year 2025 revenue of $727 million. The new product is expected to contribute to this growth trajectory by broadening the company’s diagnostic footprint and deepening relationships with community oncology practices.
"Every delay or unanswered question in the diagnostic process can affect how quickly patients begin treatment," said Tony Zook, chief executive officer at NeoGenomics. "PanTracer Pro is designed to help clinicians get the information they need earlier and more reliably, so care teams can plan next steps with greater clarity and confidence across the care journey."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.